by Desiree Cobb-Olori | Feb 6, 2025
NF-L is a validated biomarker for assessing disease progression, intensity, and treatment response across a wide range of neurodegenerative disorders including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis...
by Desiree Cobb-Olori | Jan 28, 2025
Fragile X Syndrome (FXS) is a genetic disorder caused by a CGG expansion in the Fmr1 gene. This condition tends to affect males more severely, while females often present a mosaic pattern of effects. Symptoms of FXS include: delayed crawling and walking, speech...
by susan.forootan | Aug 6, 2024
The B6.Cg-Tg(HD exon1)61Gpb/J mouse line, or R6/1, is a Huntington’s disease model that carries the human huntingtin gene’s 5’ end (116-120 CAG repeats). Similar to the R6/2 mice, these mice motor deficits, seizures, reduced body weight, and muscle mass, however,...
by Kelly Morris | Jun 27, 2024
Traumatic brain injury (TBI) is termed a silent epidemic, with the US CDC reporting approximately 190 American deaths from TBI daily. The controlled cortical impact (CCI) model of TBI is the most accurate of the preclinical TBI models with controlled biomechanical...
by susan.forootan | May 20, 2024
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive loss of upper and lower motor neurons producing muscle denervation, motor impairments, and brain atrophy. Deposition of insoluble cytosolic inclusions of Transactive...
